# ENDRA Life Sciences Inc.: Form 10-Q for the period ended Mar 31, 2023

- Company: [ENDRA Life Sciences Inc.](/companies/ndra.md) (CIK 1681682)
- Form: 10-Q
- Filed: 2023-05-15
- Accepted by EDGAR: May 15, 2023, 16:55 ET
- Period: 2023-03-31
- Accession: 0001654954-23-006594
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1681682/000165495423006594/ndra_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1681682/000165495423006594/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2023-01-01 to 2023-03-31 | $1.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | −$2.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months, 2023-01-01 to 2023-03-31 | −$2.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2023-01-01 to 2023-03-31 | $27.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-03-31 | $2.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $5.5m | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $6.7m | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $1.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $2.2m | us-gaap:Liabilities |
| Long-term debt | at 2023-03-31 | $324.1k | us-gaap:LongTermDebt |
| Shareholders' equity | at 2023-03-31 | $4.5m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1681682/000165495423006594/ndra_10q.htm

Filed May 15, 2023.
Source: SEC EDGAR, the filing index for accession 0001654954-23-006594. Last ingested by Listed: Nov 10, 2026, 17:03 ET. No prices; not investment advice.
